5-Amino-1MQ

The single most important fact about 5-amino-1MQ comes first: it is not a peptide. A peptide is a chain of amino acids joined by peptide bonds, typically between 2 and 50 residues. 5-amino-1MQ has no amino acids and no peptide bonds. It is a small synthetic organic molecule built on a quinoline ring, closer in chemical character to a classical drug-like compound than to anything in the peptide world.

So why does it appear in peptide catalogs, peptide forums and peptide comparison tables? For commercial reasons rather than biochemical ones. The vendors that supply research peptides have gradually widened their shelves to include any compound with a metabolic or anti-aging narrative, and 5-amino-1MQ arrived with one of the most marketable narratives available: an enzyme inhibitor said to raise NAD+ in fat cells. Shared distribution channels created a shared label, and the label is inaccurate.

This distinction matters for practical reasons, not just pedantic ones. Peptides and small molecules behave differently in the body: they are absorbed differently, broken down differently, distributed differently and cleared differently. A peptide given by mouth is usually digested into fragments before it can act, which is why most research peptides are supplied as lyophilized powder for reconstitution. A stable small cation like 5-amino-1MQ has no such constraint, which is exactly why it reaches the market as capsules. Reasoning about it by analogy with mitochondrial peptides such as MOTS-c or with injectable research peptides will lead you to the wrong conclusions about absorption, duration of action and risk profile.

Throughout this guide, 5-amino-1MQ is therefore described as what it is: an investigational small molecule NNMT inhibitor whose entire published evidence base is preclinical. Nothing in this article is a recommendation to use it, and no dose or regimen is provided anywhere in the text.

The full chemical name is 5-amino-1-methylquinolinium. The parent structure is quinoline, a two-ring aromatic system with one nitrogen atom. Two modifications define the compound: a methyl group attached to the ring nitrogen, which gives the molecule a permanent positive charge, and an amino group at position 5 of the ring. Because the molecule is a cation, it must be supplied with a counter-ion, and the material used in research and sold commercially is usually the iodide salt (C₁₀H₁₁IN₂, about 286.11 g/mol; the cation itself is about 159.21 g/mol).

That permanent positive charge is not a chemical curiosity. It is central to the design logic. The natural substrate of the NNMT enzyme is nicotinamide, and the product of the reaction, 1-methylnicotinamide, is itself a methylated positively charged pyridinium species. 5-amino-1MQ was developed within a series of quinolinium compounds intended to resemble that product closely enough to occupy the enzyme's nicotinamide binding site while remaining able to cross cell membranes, a combination that earlier charged inhibitors struggled to achieve.

Chemists working in this area published structure-activity work on the quinolinium series before the compound reached consumer channels, and the medicinal chemistry program behind it is documented in the peer-reviewed literature and in patent filings on quinoline-derived NNMT inhibitors. In the primary papers, the compound is often referred to generically as NNMTi rather than by the consumer name 5-amino-1MQ, which is one reason the literature can be hard to find for a non-specialist reader.

Two properties are worth holding onto. First, it is small and stable, so it survives handling and, in rodents, oral administration. Second, it is charged, which influences how it distributes across tissues and how it is eliminated. Neither property has been characterized in humans: there is no published human absorption, distribution, metabolism or excretion data for this molecule.

The proposed mechanism runs through a single enzyme: nicotinamide N-methyltransferase (NNMT). NNMT catalyzes one reaction. It takes a methyl group from S-adenosyl-L-methionine (SAM), the cell's universal methyl donor, and attaches it to nicotinamide, the amide form of vitamin B3. The products are 1-methylnicotinamide, which is largely destined for urinary excretion, and S-adenosyl-L-homocysteine (SAH).

For decades this was regarded mainly as a clearance route for excess vitamin B3. A 2017 review by Pissios in Trends in Endocrinology and Metabolism set out the case that NNMT is better understood as a metabolic node: it sits at the intersection of NAD+ availability, one-carbon and methyl-group metabolism, and the downstream signaling that depends on both. Interest intensified because NNMT expression is elevated in the adipose tissue and liver of obese and insulin-resistant animals, and in several human cancers.

If you inhibit that single reaction, three consequences follow logically inside the cell, and all three were measured by Neelakantan and colleagues in cultured adipocytes treated with quinolinium NNMT inhibitors: intracellular 1-methylnicotinamide fell, intracellular NAD+ and SAM rose, and lipogenesis was suppressed. In other words, the methyl donor is spared because it is no longer being spent on nicotinamide, and the nicotinamide itself is spared because it is no longer being tagged for excretion.

From there, the proposed chain becomes more speculative. Higher NAD+ is expected to support the activity of NAD+-dependent enzymes, including the sirtuins and PARPs, and higher SAM alters the substrate supply for methylation reactions on DNA, histones and proteins. Those are plausible mechanistic consequences with experimental support in cells, but the step from "an enzyme was inhibited in a mouse adipocyte" to "a measurable clinical outcome in a person" has not been taken for this compound. The mechanism is a hypothesis about humans, not a finding in humans.

5-amino-1MQ is marketed in the same conversation as NAD+ precursors because of a genuine biochemical relationship, but the relationship is indirect and often overstated. 5-amino-1MQ is not a source of NAD+. It supplies no nicotinamide, no nicotinamide riboside, no nicotinamide mononucleotide and no building block of any kind. It acts on the other side of the ledger.

Most NAD+ in mammalian cells is regenerated rather than synthesized from scratch. Enzymes that consume NAD+, such as sirtuins, PARPs and CD38, release nicotinamide, and the salvage pathway recycles that nicotinamide back into NAD+ through NAMPT and NMNAT. NNMT competes for the same pool of nicotinamide: whatever it methylates leaves the recycling loop permanently. Blocking NNMT therefore leaves a larger fraction of nicotinamide inside the salvage loop. The analogy that holds is a drain rather than a tap: supplementing a precursor is adding water, while inhibiting NNMT is narrowing the outflow.

How much that narrowing matters depends entirely on the tissue and the context. NNMT expression varies widely across tissues, being high in liver and adipose tissue and much lower elsewhere, and it rises in obesity and with age. If NNMT activity is low in a given tissue, inhibiting it changes very little. This is one reason the preclinical work has concentrated on adipose tissue, liver and aged skeletal muscle rather than on whole-body NAD+ as a single number.

Readers comparing approaches to NAD+ biology may find the background on NAD+ products and how they are supplied useful for context. The honest summary is that no published study has demonstrated that 5-amino-1MQ raises NAD+ in any human tissue. The NAD+ claims attached to it in marketing copy are extrapolations from rodent and cell data, and they should be read as such.

The evidence base is real, it is peer-reviewed, and it is entirely preclinical. It is worth walking through the main entries, because the gap between what they show and what is claimed online is where most of the confusion lives.

The foundation is genetic rather than pharmacological. In 2014, Kraus and colleagues reported in Nature that knocking down NNMT in adipose tissue and liver using an antisense oligonucleotide protected mice from diet-induced obesity, with increased energy expenditure and greater leanness, and proposed NNMT as a target in obesity and type 2 diabetes. This established the target; it did not test 5-amino-1MQ.

The pharmacological work followed. Neelakantan and colleagues reported in Biochemical Pharmacology in 2018 that selective, membrane-permeable small molecule NNMT inhibitors from the quinolinium series lowered intracellular 1-methylnicotinamide, raised intracellular NAD+ and SAM, suppressed adipocyte lipogenesis, and reversed high-fat-diet-induced obesity in mice. The same group then extended the work in two directions. A 2019 paper in the same journal examined an NNMT inhibitor in aged skeletal muscle and senescent muscle stem cells, reporting enhanced myoblast differentiation and improved regenerative capacity. A 2021 report in Scientific Reports by Sampson and colleagues combined NNMT inhibition with a reduced-calorie, lower-fat diet in diet-induced obese mice and found that the combination improved body weight and fat loss and normalized body composition parameters relative to diet alone.

More recently, Dimet-Wiley and colleagues reported in Scientific Reports in 2024 that NNMT inhibition in aged mice both mimicked and added to the muscle-function benefits of exercise, with treated sedentary animals showing improved grip strength relative to sedentary controls. Separately, Kannt and colleagues published in 2018 on a structurally different NNMT inhibitor, JBSNF-000088, reporting reduced 1-methylnicotinamide levels alongside insulin sensitization and body weight reduction in animal models of metabolic disease, which suggests the effects track the target rather than one specific chemical scaffold.

Here is the limit, stated plainly. Every result above comes from cells or rodents. No published human clinical trial of 5-amino-1MQ exists, and searches of trial registries for the compound, its full chemical name and the drug class return no registered study at any phase. Mouse obesity models respond to many interventions that fail in people, and the species difference in NNMT biology has not been resolved. Treat every number you see quoted for 5-amino-1MQ in a human context as unsourced.

Because 5-amino-1MQ shares a shelf with research peptides, it is routinely compared with them. The comparison is instructive as long as the categories stay distinct.

The second contrast is about evidence tiers, and it is the one most often collapsed in marketing. Within the broad category of compounds discussed for body composition, there are approved medicines with large randomized human trials, there are research peptides with animal data and scattered human reports, and there are compounds like 5-amino-1MQ with preclinical data only. Those are three different epistemic situations, and a product page that lists them side by side in the same tone is misleading its reader. Our overviews of peptides discussed for fat loss and of how peptides are proposed to influence weight cover where the respective evidence lines actually stand.

The third contrast concerns mechanism. The approved weight-management drugs act on appetite and gastric emptying through receptor signaling, with effects a patient can perceive. The proposed NNMT mechanism is a change in intracellular cofactor availability inside fat cells, which produces no sensation at all. That absence of felt effect is worth noting, because it means a user has no feedback signal of any kind, neither for benefit nor for harm.

None of this makes 5-amino-1MQ uninteresting. NNMT is a credible metabolic target with a decade of serious work behind it. It makes 5-amino-1MQ early, which is a different thing from promising, and a very different thing from established.

Format follows chemistry. Peptides are vulnerable to the digestive tract: gastric acid and intestinal proteases cleave peptide bonds, so an orally swallowed peptide is usually degraded into fragments before it can reach its target. This is why research peptides overwhelmingly arrive as powder in a vial intended for reconstitution, and why oral peptide medicines require either substantial chemical modification or specialized absorption enhancers.

5-amino-1MQ has none of those liabilities. It has no peptide bond to cleave, it is a small and chemically robust aromatic cation, and in the published rodent work compounds in this series were administered successfully, including by routes compatible with systemic exposure. A stable small molecule can be put into a capsule without a formulation program, so that is what vendors do.

It is important to separate two claims that the capsule format quietly blurs. "This molecule is chemically stable enough to be swallowed" is well supported. "Swallowing this molecule produces useful blood and tissue concentrations in a human being" is not: there is no published human pharmacokinetic study, which means oral bioavailability, half-life, tissue distribution and elimination route in humans are all undetermined. A capsule looks reassuringly like a supplement, and the resemblance is cosmetic.

The capsule format also introduces quality questions distinct from those surrounding vials. Capsule contents cannot be visually assessed, the labeled amount per capsule cannot be verified by the end user, and independent analyses of unregulated capsule products across this market have repeatedly found content that departs from the label. Since 5-amino-1MQ is not manufactured to pharmaceutical standards for human use, identity, purity, residual solvents and excipients are all left to the supplier's own documentation. Where a certificate of analysis is provided, its date, the batch it refers to and the laboratory that produced it are what give it any meaning.

The accurate answer is that the human safety of 5-amino-1MQ is unknown. This is not a stylistic hedge. There is no published human trial, no registered trial, no published human pharmacokinetic study and no formal pharmacovigilance database for this compound. There is therefore no established adverse event profile, no characterized interaction profile and no evidence-based guidance on who should avoid it. Any confident safety statement you encounter, in either direction, is being made without data.

What can be discussed are theoretical considerations that follow from the mechanism, presented as questions that remain open rather than as predicted harms. Inhibiting NNMT raises intracellular SAM, and SAM is the methyl donor for DNA, histone and protein methylation, so a sustained shift in methyl-group availability is a plausible route to effects far beyond adipose tissue, including on gene expression. Inhibiting NNMT also reduces production of 1-methylnicotinamide, a metabolite with reported biological activities of its own rather than an inert waste product, and the consequences of suppressing it chronically in humans have not been studied. NNMT expression in tumor biology has been studied in both directions depending on tumor type, which is a reason for caution rather than a demonstrated risk. None of these mechanisms has been shown to cause harm in people; equally, none has been shown not to.

The duration question deserves emphasis. The rodent studies ran for defined experimental periods under controlled conditions. Open-ended use by an adult human, potentially alongside prescription medicines, other supplements and existing medical conditions, is not a scenario any published study has examined.

Our general discussion of how to think about the safety of unapproved research compounds applies here with one addition: a small molecule enzyme inhibitor can reach intracellular targets throughout the body, so the reasoning used for a receptor-targeted peptide does not transfer. This article is for educational purposes only and is not medical advice. 5-amino-1MQ is not approved for human use. Consult a qualified healthcare professional before considering any unapproved compound, particularly if you take prescription medication, are pregnant or breastfeeding, or have an existing medical condition.

5-amino-1MQ is not an approved medicine in the United States, the European Union or, to the best of available public information, any other major jurisdiction. It has no approved indication, no approved label, no approved dose and no marketing authorization. It has not completed, or even publicly entered, the clinical development process that would be required to obtain one.

It is also not an authorized food supplement ingredient. In the United States, a newly synthesized compound with no history of use in the food supply does not meet the statutory definition of a dietary ingredient, and the FDA has issued warning letters to companies marketing unapproved compounds of this kind with disease or body composition claims. In the European Union, a synthetic substance without a documented history of significant consumption before May 1997 falls under the novel food framework and requires authorization before it may be sold for human consumption. Neither route has been completed for 5-amino-1MQ.

What vendors do instead is sell it with a research-use qualifier: "for laboratory research only", "not for human consumption". That language is a legal position taken by the seller, not a safety assessment and not a form of approval. It also does not resolve the buyer's own legal situation, which varies by country and can differ for possession, importation and resale. Customs treatment of such shipments varies considerably between jurisdictions.

Athletes have an additional concern. The WADA Prohibited List includes a category covering any pharmacological substance that has no current approval by a governmental regulatory health authority for human therapeutic use, which is a description that fits 5-amino-1MQ. Competitors subject to anti-doping rules should assume the compound is prohibited and verify with their national anti-doping organization rather than relying on the absence of its name from a list. Finally, laws change; verify the current position in your own jurisdiction rather than relying on any article, including this one.

A reference guide is most useful when it is explicit about the shape of the hole in the evidence. For 5-amino-1MQ, the hole is large and it is specifically human-shaped.

Human pharmacokinetics are unknown. No published study establishes how much of an oral dose is absorbed in a person, what blood concentrations result, how long the compound persists, which tissues it reaches, whether it is metabolized and how it is eliminated. Without these parameters, the concentrations that produced effects in cultured cells cannot be related to anything that happens in a human body.

Human target engagement is unknown. The mechanism predicts a measurable fall in 1-methylnicotinamide if NNMT is being inhibited, which is a tractable biomarker. No published human study reports it for this compound, so there is no evidence that the enzyme is actually being inhibited in people at any exposure achievable by the marketed format.

Human efficacy is unknown. There is no trial of body weight, fat mass, insulin sensitivity, muscle strength or any other outcome. Human safety is unknown, including long-term consequences of sustained changes in methyl-donor availability, effects in older adults and in people with liver or kidney impairment, and interactions with medicines. Tissue selectivity is unknown: NNMT is expressed in liver, adipose tissue and elsewhere, and a systemically distributed inhibitor does not act only where a marketer would like it to.

Two further unknowns are worth naming. The consequences of the SAM increase on epigenetic regulation have not been characterized in humans, and the long-term significance of suppressing 1-methylnicotinamide, a metabolite with its own reported activities, has not been established. What would change this picture is ordinary and specific: a published Phase I study with pharmacokinetics and a target-engagement biomarker, followed by controlled trials with predefined outcomes. Until something of that kind exists, 5-amino-1MQ remains an interesting probe of a credible metabolic target, and nothing more that can be said responsibly.